Natera, Inc. Q3 2026 Earnings Call Summary

Strategic Leadership Transition and Oncology-Driven Growth

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Revenue growth of >40% excluding true-ups was driven by record Signatera MRD volumes and a significant surge in biopharma demand following the IMvigor011 trial readout.

• The company is transitioning leadership from Steven Chapman to Solomon Moshkevich, emphasizing strategic continuity and execution from a position of financial and operational strength.

• Gross margin expansion to 63.2% excluding true-ups reflects operational leverage as volumes scale, supply chain renegotiations, and sequential ASP improvements.

• Biopharma revenue grew 70-75% in 2025, supported by the launch of Signatera Genome with phased variants which management believes has settled the debate over technical leadership.

• Organ health volumes increased nearly 40% year-over-year, benefiting from the implementation of Medicare coverage for surveillance that took effect in late August.

• Management attributes the 56% growth in clinical MRD units to the full onboarding of the commercial team and increased adoption across new indications beyond colorectal and breast cancer.

Path to $6 Billion Revenue and Market Expansion

• Management established a long-term goal to double annual revenue to $6 billion by 2029, a target they believe is achievable with minimal contribution from the emerging cancer screening business.

• The 2026 revenue guidance was raised by $140 million at the midpoint to over $3 billion, assuming steady ASPs and continued volume momentum into the fourth quarter.

• Preliminary 2027 planning assumes 10-12% OpEx growth to support high-ROI investments in pharma services, data licensing, and the FIND study readout.

• The Japan launch for colorectal and bladder cancer remains on track, with reimbursement pricing expected to be finalized and potentially accretive to U.S. ASP levels by early 2027.

• Management expects to reach the $6 billion target by achieving Signatera ASPs of approximately $1,450, while maintaining a long-term aspirational target of $2,000 per test.

Regulatory Milestones and Clinical Progress

• Medicare granted coverage for serial Signatera use in early-stage hepatocellular carcinoma (HCC), an indication affecting approximately 40,000 new patients annually in the U.S.

• The FDA granted breakthrough device designation to the multi-cancer early detection assay, providing a more collaborative and expedited regulatory path forward.

• The FIND study successfully completed enrollment of 30,000 patients in the PMA cohort, positioning the company for a definitive colorectal cancer readout in 2027.

• Regulatory approval was achieved for Signatera in bladder cancer in Japan, leading to consolidated pricing discussions with the health ministry for both CRC and bladder indications.